Latest News

Thermalin Diabetes gets $4.5M NIH grant for next-generation insulin

Monday, April 30th, 2012

Next-generation insulin developer Thermalin Diabetes has received a $4.5 million grant from the National Institutes of Health to continue development of its insulin analogs. The grant is expected to fund Cleveland-based Thermalin through the filing of an investigational new drug (IND) application for a rapid-acting insulin analog drug candidate, CEO Rick Berenson said.

Continue reading.

PNC Bank building resource center in Cleveland’s Fairfax neighborhood

Friday, March 23rd, 2012

CLEVELAND, Ohio — PNC Bank is building a $5 million resource center in Cleveland’s Fairfax neighborhood to provide educational programs and to cultivate the area’s rich heritage. “We’re very proud of this unique collaboration,” said regional PNC manager Paul Clark, who on Wednesday announced creation of the PNC Fairfax Connection during a gathering at the [...]

Continue reading.

Venture groups: Sustained investment needed in Knowledge District

Friday, March 23rd, 2012

PROVIDENCE – Leaders from three prominent nonprofit technology venture groups said Tuesday that Rhode Island is well-positioned to expand its creative economy with sustained investments from the government, research institutions and businesses. The three organizations – Cleveland Clinic Innovation in Ohio, Innovation Works in Pittsburgh and University City Science Center in Philadelphia – have all [...]

Continue reading.

Cleveland Clinic extends innovation collaboration

Wednesday, February 22nd, 2012

CLEVELAND, Ohio — The Cleveland Clinic is pairing with New York’s North Shore-Long Island Jewish Health System to share its expertise in developing and marketing medical innovations.The deal, the value of which is not being disclosed, is the second such collaboration the Clinic has formed and possibly the beginning of a “national innovation alliance,” said [...]

Continue reading.

Juventas Therapeutics attracts $12 million in equity financing

Tuesday, February 14th, 2012

Juventas Therapeutics Inc. of Cleveland has raised $12 million in equity financing that it will use to finance Phase II clinical trials of a drug designed to recruit the body’s stem cells to repair damaged tissue.

Continue reading.

Are you looking for past articles? Please visit our news archive.